Hi Rebecca,
Don’t mean to be rude, but Exchanger is correct, your statement is very misleading. The Biomuse study was only still finishing enrollment recently ( 80% complete as per last quarterly report) and the study will be ongoing for 12 months as per the slides from the 10th March Global life Science conference. This means the study will not be completed until mid next year. I suggest you re read page 19 of that report which clearly shows Phase 2 commencement will begin later this year and run simultaneously with the trial.
The trial will definitely start before the completion of the study. FDA will use that information to help Alterity extract endpoints - as it was at their suggestion they do this Biomuse study in the first place by my recollection.
Hi Rebecca,Don’t mean to be rude, but Exchanger is correct, your...
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $31.42M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.6¢ | $22.49K | 3.782M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 54 | 57333068 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 4626182 | 4 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
0.6¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.6¢ | 0.6¢ | 0.6¢ | 2959000 | ||
| Last updated 14.33pm 26/04/2024 ? | |||||
| ATH (ASX) Chart |